The weight loss results achieved with GLP-1 receptor agonists—such as Semaglutide and Tirzepatide —are transformative. Patients experience significant, life-changing reductions in body weight and visceral fat. However, even after reaching your goal weight, one common challenge remains: stubborn, localized fat pockets  that resist diet and exercise. These areas (like the lower abdomen, flanks, or thighs) are genetically determined and often don't disappear completely. This is